Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Elena Verzoni, Giacomo Cartenì, Enrico Cortesi, Diana Giannarelli, Andrea De Giglio, Roberto Sabbatini, Sebastiano Buti, Sabrina Rossetti, Francesco Cognetti, Francesca Rastelli, Alberto Sobrero, Daniele Turci, Cora N Sternberg, Camillo Porta, Federico Cappuzzo, Giampaolo Tortora, Davide Tassinari, Stefano Panni, Antonio Pazzola, Gianmarco Surico, Alessandra Raimondi, Ugo De Giorgi, Giuseppe Procopio

ABSTRACT

BACKGROUND: The Italian Renal Cell Cancer Early Access Program was an expanded access program that allowed access to nivolumab, for patients (pts) with metastatic renal cell carcinoma (mRCC) prior to regulatory approval. METHODS: Pts with previously treated advanced or mRCC were eligible to receive nivolumab 3 mg/kg every 2 weeks. Pts included in the analysis had received ≥1 dose of nivolumab and were monitored for drug-related adverse events (drAEs) using CTCAE v.4.0. Immune-related (ir) AEs were defined as AEs displaying a certain, likely or possible correlation with immunotherapy (cutaneous, endocrine, hepatic, gastro-intestinal and pulmonary). The association between overall survival (OS) and irAEs was assessed, and associations between variables were evaluated with a logistic regression model. RESULTS: A total of 389 pts were enrolled between July 2015 and April 2016. Overall, the objective response rate was 23.1%. At a median follow-up of 12 months, the median progression-free survival was 4.5 months (95% CI 3.7-6.2) and the 12-month overall survival rate was 63%. Any grade and grade 3-4 drAEs were reported in 124 (32%) and 27 (7%) of pts, respectively, and there were no treatment-related deaths. Any grade irAEs occurred in 76 (20%) of patients, 8% cutaneous, 4% endocrine, 2% hepatic, 5% gastro-intestinal and 1% pulmonary. Of the 22 drAEs inducing treatment discontinuation, 10 (45%) were irAEs. Pts with drAEs had a significantly longer survival than those without drAEs (median OS 22.5 versus 16.4 months, p = 0.01). Pts with irAEs versus without irAEs had a more significant survival benefit (median OS not reached versus 16.8 months, p = 0.002), confirmed at the landmark analysis at 6 weeks. The occurrence of irAEs displayed a strong association with OS in univariable (HR 0.48, p = 0.003) and multivariable (HR 0.57, p = 0.02) analysis. CONCLUSIONS: The appearance of irAEs strongly correlates with survival benefit in a real-life population of mRCC pts treated with nivolumab. More... »

PAGES

99

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s40425-019-0579-z

DOI

http://dx.doi.org/10.1186/s40425-019-0579-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113181867

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30944023


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Istituto Nazionale dei Tumori", 
          "id": "https://www.grid.ac/institutes/grid.417893.0", 
          "name": [
            "Medical Oncology-Genitourinary Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Via Venezian 1, 20133, Milan, Italy. elena.verzoni@istitutotumori.mi.it."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Verzoni", 
        "givenName": "Elena", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ospedale Antonio Cardarelli", 
          "id": "https://www.grid.ac/institutes/grid.413172.2", 
          "name": [
            "Oncology Unit, A. Cardarelli Hospital, Naples, Italy."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Carten\u00ec", 
        "givenName": "Giacomo", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Policlinico Umberto I", 
          "id": "https://www.grid.ac/institutes/grid.417007.5", 
          "name": [
            "Radiology, Oncology and Pathology, Policlinico Umberto I, Rome, Italy."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cortesi", 
        "givenName": "Enrico", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Istituti Fisioterapici Ospitalieri", 
          "id": "https://www.grid.ac/institutes/grid.417520.5", 
          "name": [
            "Biostatistical Unit, Regina Elena National Cancer Institute - IRCCS, Rome, Italy."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Giannarelli", 
        "givenName": "Diana", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Azienda Ospedaliera S.Maria", 
          "id": "https://www.grid.ac/institutes/grid.416377.0", 
          "name": [
            "Medical Oncology, Azienda Ospedaliera Santa Maria, Terni, Italy."
          ], 
          "type": "Organization"
        }, 
        "familyName": "De Giglio", 
        "givenName": "Andrea", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Policlinico di Modena", 
          "id": "https://www.grid.ac/institutes/grid.413363.0", 
          "name": [
            "Oncology and Hematology Department, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sabbatini", 
        "givenName": "Roberto", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ospedale di Parma", 
          "id": "https://www.grid.ac/institutes/grid.411482.a", 
          "name": [
            "Medical Oncology, Azienda Ospedaliera di Parma, Parma, Italy."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Buti", 
        "givenName": "Sebastiano", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Istituto Nazionale dei Tumori", 
          "id": "https://www.grid.ac/institutes/grid.417893.0", 
          "name": [
            "Urology and Gynecology, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Naples, Italy."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rossetti", 
        "givenName": "Sabrina", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Istituti Fisioterapici Ospitalieri", 
          "id": "https://www.grid.ac/institutes/grid.417520.5", 
          "name": [
            "Medical Oncology, Regina Elena National Cancer Institute - IRCCS, Rome, Italy."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cognetti", 
        "givenName": "Francesco", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Medical Oncology, UOC Oncologia Area Vasta 4, Fermo, Italy."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rastelli", 
        "givenName": "Francesca", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ospedale San Martino", 
          "id": "https://www.grid.ac/institutes/grid.410345.7", 
          "name": [
            "Medical Oncology, San Martino Hospital, Genoa, Italy."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sobrero", 
        "givenName": "Alberto", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ospedale Santa Maria delle Croci", 
          "id": "https://www.grid.ac/institutes/grid.415207.5", 
          "name": [
            "Medical Oncology, Ospedale Santa Maria delle Croci, Ravenna, Italy."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Turci", 
        "givenName": "Daniele", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Medical Oncology, Azienda Ospedaliera S. Camillo Forlanini, Rome, Italy."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sternberg", 
        "givenName": "Cora N", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Pavia", 
          "id": "https://www.grid.ac/institutes/grid.8982.b", 
          "name": [
            "Department of Internal Medicine, University of Pavia and Division of Translational Oncology, IRCCS Istituti Clinici Scientifici Maugeri, Pavia, Italy."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Porta", 
        "givenName": "Camillo", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Medical Oncology, Ospedale Umberto I (AUSL Romagna), Lugo, Italy."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cappuzzo", 
        "givenName": "Federico", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Medical Oncology, AOU Integrata Verona \"Borgo Roma\", Verona, Italy."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tortora", 
        "givenName": "Giampaolo", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ospedale Infermi di Rimini", 
          "id": "https://www.grid.ac/institutes/grid.414614.2", 
          "name": [
            "Oncology, Ospedale Infermi, Rimini, Italy."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tassinari", 
        "givenName": "Davide", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Istituti Ospitalieri di Cremona", 
          "id": "https://www.grid.ac/institutes/grid.419450.d", 
          "name": [
            "Medical Oncology, Istituti Ospitalieri di Cremona, Cremona, Italy."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Panni", 
        "givenName": "Stefano", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Medical Oncology, Ospedale Civile SS Annunziata, Sassari, Italy."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pazzola", 
        "givenName": "Antonio", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ospedale Vito Fazzi", 
          "id": "https://www.grid.ac/institutes/grid.417011.2", 
          "name": [
            "Medical Oncology, Ospedale Vito Fazzi, Lecce, Italy."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Surico", 
        "givenName": "Gianmarco", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Istituto Nazionale dei Tumori", 
          "id": "https://www.grid.ac/institutes/grid.417893.0", 
          "name": [
            "Medical Oncology-Genitourinary Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Via Venezian 1, 20133, Milan, Italy."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Raimondi", 
        "givenName": "Alessandra", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori", 
          "id": "https://www.grid.ac/institutes/grid.419563.c", 
          "name": [
            "Urologic-Gynecologic Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy."
          ], 
          "type": "Organization"
        }, 
        "familyName": "De Giorgi", 
        "givenName": "Ugo", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Istituto Nazionale dei Tumori", 
          "id": "https://www.grid.ac/institutes/grid.417893.0", 
          "name": [
            "Medical Oncology-Genitourinary Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Via Venezian 1, 20133, Milan, Italy."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Procopio", 
        "givenName": "Giuseppe", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1097/cji.0000000000000046", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006229006"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cji.0000000000000046", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006229006"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/17425255.2016.1214713", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006340760"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2015.60.8448", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009760042"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cji.0b013e318156e47e", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015171108"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cji.0b013e318156e47e", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015171108"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jamaoncol.2015.2274", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017475370"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1510665", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019970557"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.06.205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021025524"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.06.205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021025524"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0053745", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032246329"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jamadermatol.2015.1916", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032824188"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2015.11.016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034148114"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1200690", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042896583"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2014.57.4756", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043986240"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-07-0187", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049037424"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/2162402x.2016.1231292", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1058420756"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdw640", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059394941"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-15-1136", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063224982"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2015.66.1389", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079388627"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.eururo.2017.02.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084074059"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.eururo.2017.02.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084074059"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1634/theoncologist.2017-0133", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1086386152"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.0000000000004359", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091248943"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.0000000000004359", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091248943"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.0000000000004359", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091248943"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jtho.2017.08.022", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091880982"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3390/cancers10020032", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100657075"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2017.77.6385", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101034912"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1634/theoncologist.2017-0384", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105038826"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/bju.14461", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105203453"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2016.34.15_suppl.3047", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106841583"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12", 
    "datePublishedReg": "2019-12-01", 
    "description": "BACKGROUND: The Italian Renal Cell Cancer Early Access Program was an expanded access program that allowed access to nivolumab, for patients (pts) with metastatic renal cell carcinoma (mRCC) prior to regulatory approval.\nMETHODS: Pts with previously treated advanced or mRCC were eligible to receive nivolumab 3\u2009mg/kg every 2\u2009weeks. Pts included in the analysis had received \u22651 dose of nivolumab and were monitored for drug-related adverse events (drAEs) using CTCAE v.4.0. Immune-related (ir) AEs were defined as AEs displaying a certain, likely or possible correlation with immunotherapy (cutaneous, endocrine, hepatic, gastro-intestinal and pulmonary). The association between overall survival (OS) and irAEs was assessed, and associations between variables were evaluated with a logistic regression model.\nRESULTS: A total of 389 pts were enrolled between July 2015 and April 2016. Overall, the objective response rate was 23.1%. At a median follow-up of 12\u2009months, the median progression-free survival was 4.5\u2009months (95% CI 3.7-6.2) and the 12-month overall survival rate was 63%. Any grade and grade 3-4 drAEs were reported in 124 (32%) and 27 (7%) of pts, respectively, and there were no treatment-related deaths. Any grade irAEs occurred in 76 (20%) of patients, 8% cutaneous, 4% endocrine, 2% hepatic, 5% gastro-intestinal and 1% pulmonary. Of the 22 drAEs inducing treatment discontinuation, 10 (45%) were irAEs. Pts with drAEs had a significantly longer survival than those without drAEs (median OS 22.5 versus 16.4\u2009months, p\u2009=\u20090.01). Pts with irAEs versus without irAEs had a more significant survival benefit (median OS not reached versus 16.8\u2009months, p\u2009=\u20090.002), confirmed at the landmark analysis at 6\u2009weeks. The occurrence of irAEs displayed a strong association with OS in univariable (HR 0.48, p\u2009=\u20090.003) and multivariable (HR 0.57, p\u2009=\u20090.02) analysis.\nCONCLUSIONS: The appearance of irAEs strongly correlates with survival benefit in a real-life population of mRCC pts treated with nivolumab.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s40425-019-0579-z", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1049249", 
        "issn": [
          "2051-1426"
        ], 
        "name": "Journal for ImmunoTherapy of Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "7"
      }
    ], 
    "name": "Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.", 
    "pagination": "99", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s40425-019-0579-z"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113181867"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101620585"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30944023"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s40425-019-0579-z", 
      "https://app.dimensions.ai/details/publication/pub.1113181867"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-15T09:01", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000375_0000000375/records_91444_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://jitc.biomedcentral.com/articles/10.1186/s40425-019-0579-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s40425-019-0579-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s40425-019-0579-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s40425-019-0579-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s40425-019-0579-z'


 

This table displays all metadata directly associated to this object as RDF triples.

325 TRIPLES      21 PREDICATES      54 URIs      20 LITERALS      8 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s40425-019-0579-z schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N1096632974504695a5cdced5b51e7c9c
4 schema:citation https://doi.org/10.1001/jamadermatol.2015.1916
5 https://doi.org/10.1001/jamaoncol.2015.2274
6 https://doi.org/10.1016/j.ejca.2015.11.016
7 https://doi.org/10.1016/j.eururo.2017.02.010
8 https://doi.org/10.1016/j.jtho.2017.08.022
9 https://doi.org/10.1056/nejmoa1200690
10 https://doi.org/10.1056/nejmoa1510665
11 https://doi.org/10.1080/17425255.2016.1214713
12 https://doi.org/10.1080/2162402x.2016.1231292
13 https://doi.org/10.1093/annonc/mdw640
14 https://doi.org/10.1097/cji.0000000000000046
15 https://doi.org/10.1097/cji.0b013e318156e47e
16 https://doi.org/10.1111/bju.14461
17 https://doi.org/10.1158/1078-0432.ccr-07-0187
18 https://doi.org/10.1158/1078-0432.ccr-15-1136
19 https://doi.org/10.1200/jco.2005.06.205
20 https://doi.org/10.1200/jco.2014.57.4756
21 https://doi.org/10.1200/jco.2015.60.8448
22 https://doi.org/10.1200/jco.2015.66.1389
23 https://doi.org/10.1200/jco.2016.34.15_suppl.3047
24 https://doi.org/10.1200/jco.2017.77.6385
25 https://doi.org/10.1212/wnl.0000000000004359
26 https://doi.org/10.1371/journal.pone.0053745
27 https://doi.org/10.1634/theoncologist.2017-0133
28 https://doi.org/10.1634/theoncologist.2017-0384
29 https://doi.org/10.3390/cancers10020032
30 schema:datePublished 2019-12
31 schema:datePublishedReg 2019-12-01
32 schema:description BACKGROUND: The Italian Renal Cell Cancer Early Access Program was an expanded access program that allowed access to nivolumab, for patients (pts) with metastatic renal cell carcinoma (mRCC) prior to regulatory approval. METHODS: Pts with previously treated advanced or mRCC were eligible to receive nivolumab 3 mg/kg every 2 weeks. Pts included in the analysis had received ≥1 dose of nivolumab and were monitored for drug-related adverse events (drAEs) using CTCAE v.4.0. Immune-related (ir) AEs were defined as AEs displaying a certain, likely or possible correlation with immunotherapy (cutaneous, endocrine, hepatic, gastro-intestinal and pulmonary). The association between overall survival (OS) and irAEs was assessed, and associations between variables were evaluated with a logistic regression model. RESULTS: A total of 389 pts were enrolled between July 2015 and April 2016. Overall, the objective response rate was 23.1%. At a median follow-up of 12 months, the median progression-free survival was 4.5 months (95% CI 3.7-6.2) and the 12-month overall survival rate was 63%. Any grade and grade 3-4 drAEs were reported in 124 (32%) and 27 (7%) of pts, respectively, and there were no treatment-related deaths. Any grade irAEs occurred in 76 (20%) of patients, 8% cutaneous, 4% endocrine, 2% hepatic, 5% gastro-intestinal and 1% pulmonary. Of the 22 drAEs inducing treatment discontinuation, 10 (45%) were irAEs. Pts with drAEs had a significantly longer survival than those without drAEs (median OS 22.5 versus 16.4 months, p = 0.01). Pts with irAEs versus without irAEs had a more significant survival benefit (median OS not reached versus 16.8 months, p = 0.002), confirmed at the landmark analysis at 6 weeks. The occurrence of irAEs displayed a strong association with OS in univariable (HR 0.48, p = 0.003) and multivariable (HR 0.57, p = 0.02) analysis. CONCLUSIONS: The appearance of irAEs strongly correlates with survival benefit in a real-life population of mRCC pts treated with nivolumab.
33 schema:genre research_article
34 schema:inLanguage en
35 schema:isAccessibleForFree true
36 schema:isPartOf N639c54ebcf2e46a5a1316b9620fcd372
37 Nbc840e131bc64709b821d02de5bc342a
38 sg:journal.1049249
39 schema:name Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.
40 schema:pagination 99
41 schema:productId N273f904c38844f30bae01378a5706306
42 N2aa0a0800ea244ec875ed7432eb8eafe
43 Nb6dbe48cfc9041529f70fb4597b29aa2
44 Nf989ba2aae9d4b71b888a15d08ed93ab
45 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113181867
46 https://doi.org/10.1186/s40425-019-0579-z
47 schema:sdDatePublished 2019-04-15T09:01
48 schema:sdLicense https://scigraph.springernature.com/explorer/license/
49 schema:sdPublisher N62a933007fea4399ba91ee706404bec5
50 schema:url https://jitc.biomedcentral.com/articles/10.1186/s40425-019-0579-z
51 sgo:license sg:explorer/license/
52 sgo:sdDataset articles
53 rdf:type schema:ScholarlyArticle
54 N07013b97ddb64fd0a6d367e9556ff108 schema:affiliation https://www.grid.ac/institutes/grid.413172.2
55 schema:familyName Cartenì
56 schema:givenName Giacomo
57 rdf:type schema:Person
58 N0ba53a870c0843b98bc9e8e03c77404e schema:affiliation N78dfa4a01290454cb31e0d7cb7078e91
59 schema:familyName Sternberg
60 schema:givenName Cora N
61 rdf:type schema:Person
62 N0ee0efdd7b0f482cbd880e1fbfb4da37 schema:affiliation https://www.grid.ac/institutes/grid.416377.0
63 schema:familyName De Giglio
64 schema:givenName Andrea
65 rdf:type schema:Person
66 N1096632974504695a5cdced5b51e7c9c rdf:first N88e1ba2f20f943cba4937892bb53f41b
67 rdf:rest N6f77e23b707b4b74b85f5b23452db23e
68 N1a508a60eada40b5849dcc7f21ca70f1 rdf:first N821c9eecfe004e7faa585bbfe0fb2ee6
69 rdf:rest Ncaa9395b223f4dc99b99804dab7e945a
70 N1b72b16f1cde48358dd032b17c5327b6 schema:affiliation N3e9f4e54b6b8434e882a54c0cb2a0369
71 schema:familyName Pazzola
72 schema:givenName Antonio
73 rdf:type schema:Person
74 N272fdc97197745aa9a79935e7e691a3b rdf:first N5a3360a44b24433da186ca9b3371624f
75 rdf:rest Nd054990915b8479081442a9dd2397b03
76 N273f904c38844f30bae01378a5706306 schema:name doi
77 schema:value 10.1186/s40425-019-0579-z
78 rdf:type schema:PropertyValue
79 N2aa0a0800ea244ec875ed7432eb8eafe schema:name pubmed_id
80 schema:value 30944023
81 rdf:type schema:PropertyValue
82 N318e966f6a994631b37f4cf9d8bb6985 rdf:first N3d3ce97bafbd4286a587b4a0c9d8a905
83 rdf:rest N272fdc97197745aa9a79935e7e691a3b
84 N371cb21c2f0a43cfa112739f18644527 schema:affiliation https://www.grid.ac/institutes/grid.417011.2
85 schema:familyName Surico
86 schema:givenName Gianmarco
87 rdf:type schema:Person
88 N3d3ce97bafbd4286a587b4a0c9d8a905 schema:affiliation https://www.grid.ac/institutes/grid.413363.0
89 schema:familyName Sabbatini
90 schema:givenName Roberto
91 rdf:type schema:Person
92 N3e9f4e54b6b8434e882a54c0cb2a0369 schema:name Medical Oncology, Ospedale Civile SS Annunziata, Sassari, Italy.
93 rdf:type schema:Organization
94 N3ec497a12ef340418dbc7a44f0055243 rdf:first N98dc929168ed460ca613193d40313e4a
95 rdf:rest N9f68d82a8c8e473592fefd7dba034e07
96 N4604c8eb315b44549e6561b4886ebbf6 schema:name Medical Oncology, Ospedale Umberto I (AUSL Romagna), Lugo, Italy.
97 rdf:type schema:Organization
98 N4fe31debdf51464d940dbbbbe0a7412b rdf:first N371cb21c2f0a43cfa112739f18644527
99 rdf:rest Nfbc03964eaea4c8aa5e5b1f56d119d76
100 N50bf84228d934f49b1f66cf1e6efeb12 rdf:first Nf13bdfecb74748dd8e02ca780d5fb3f5
101 rdf:rest Na5ea016b945f4b99919c5ce382121050
102 N5a3360a44b24433da186ca9b3371624f schema:affiliation https://www.grid.ac/institutes/grid.411482.a
103 schema:familyName Buti
104 schema:givenName Sebastiano
105 rdf:type schema:Person
106 N5c005520ffc6451e91900dde5ec33462 rdf:first N89814403d016492887a47450f9f49d6a
107 rdf:rest rdf:nil
108 N5f3f3a072b4148f5a4304e3bf5e5c8de schema:affiliation https://www.grid.ac/institutes/grid.410345.7
109 schema:familyName Sobrero
110 schema:givenName Alberto
111 rdf:type schema:Person
112 N62a933007fea4399ba91ee706404bec5 schema:name Springer Nature - SN SciGraph project
113 rdf:type schema:Organization
114 N639c54ebcf2e46a5a1316b9620fcd372 schema:issueNumber 1
115 rdf:type schema:PublicationIssue
116 N6804bbb41c0844d2bf0c1ea4514c49b5 schema:name Medical Oncology, UOC Oncologia Area Vasta 4, Fermo, Italy.
117 rdf:type schema:Organization
118 N687334989a694ad68764d4e781c09e6d schema:affiliation https://www.grid.ac/institutes/grid.419563.c
119 schema:familyName De Giorgi
120 schema:givenName Ugo
121 rdf:type schema:Person
122 N6f77e23b707b4b74b85f5b23452db23e rdf:first N07013b97ddb64fd0a6d367e9556ff108
123 rdf:rest N3ec497a12ef340418dbc7a44f0055243
124 N78dfa4a01290454cb31e0d7cb7078e91 schema:name Medical Oncology, Azienda Ospedaliera S. Camillo Forlanini, Rome, Italy.
125 rdf:type schema:Organization
126 N7b03ea7b97b5461b902d2246f45ffa63 rdf:first N9528873bdb164f0abd38a34c271a2e44
127 rdf:rest Nfb2e6c402d614403b452f808ca1a47b9
128 N7c35447d437f4a83821b61c53bb85895 rdf:first Nac686b603349400c90984b9eec5b2fdb
129 rdf:rest Nbcf502627d1c4ca08781e2e031d1afa6
130 N80eecdaee6aa45b2874373c11c28c1c6 schema:affiliation https://www.grid.ac/institutes/grid.417893.0
131 schema:familyName Rossetti
132 schema:givenName Sabrina
133 rdf:type schema:Person
134 N821c9eecfe004e7faa585bbfe0fb2ee6 schema:affiliation Na5811a399822488b972d0cfe035787c0
135 schema:familyName Tortora
136 schema:givenName Giampaolo
137 rdf:type schema:Person
138 N88e1ba2f20f943cba4937892bb53f41b schema:affiliation https://www.grid.ac/institutes/grid.417893.0
139 schema:familyName Verzoni
140 schema:givenName Elena
141 rdf:type schema:Person
142 N89814403d016492887a47450f9f49d6a schema:affiliation https://www.grid.ac/institutes/grid.417893.0
143 schema:familyName Procopio
144 schema:givenName Giuseppe
145 rdf:type schema:Person
146 N8a790c7b501d466f8a580210c94ccc09 rdf:first N0ee0efdd7b0f482cbd880e1fbfb4da37
147 rdf:rest N318e966f6a994631b37f4cf9d8bb6985
148 N9528873bdb164f0abd38a34c271a2e44 schema:affiliation https://www.grid.ac/institutes/grid.8982.b
149 schema:familyName Porta
150 schema:givenName Camillo
151 rdf:type schema:Person
152 N98dc929168ed460ca613193d40313e4a schema:affiliation https://www.grid.ac/institutes/grid.417007.5
153 schema:familyName Cortesi
154 schema:givenName Enrico
155 rdf:type schema:Person
156 N9f5b60bcafe64794a235f15feb54949a schema:affiliation https://www.grid.ac/institutes/grid.417520.5
157 schema:familyName Giannarelli
158 schema:givenName Diana
159 rdf:type schema:Person
160 N9f68d82a8c8e473592fefd7dba034e07 rdf:first N9f5b60bcafe64794a235f15feb54949a
161 rdf:rest N8a790c7b501d466f8a580210c94ccc09
162 Na5811a399822488b972d0cfe035787c0 schema:name Medical Oncology, AOU Integrata Verona "Borgo Roma", Verona, Italy.
163 rdf:type schema:Organization
164 Na5ea016b945f4b99919c5ce382121050 rdf:first N0ba53a870c0843b98bc9e8e03c77404e
165 rdf:rest N7b03ea7b97b5461b902d2246f45ffa63
166 Nabee962333594ffea5fd86cce7719462 schema:affiliation N6804bbb41c0844d2bf0c1ea4514c49b5
167 schema:familyName Rastelli
168 schema:givenName Francesca
169 rdf:type schema:Person
170 Nac686b603349400c90984b9eec5b2fdb schema:affiliation https://www.grid.ac/institutes/grid.419450.d
171 schema:familyName Panni
172 schema:givenName Stefano
173 rdf:type schema:Person
174 Nb6dbe48cfc9041529f70fb4597b29aa2 schema:name nlm_unique_id
175 schema:value 101620585
176 rdf:type schema:PropertyValue
177 Nbad4545dc94848b59b40b5e9c222f858 schema:affiliation https://www.grid.ac/institutes/grid.414614.2
178 schema:familyName Tassinari
179 schema:givenName Davide
180 rdf:type schema:Person
181 Nbaf5aa6b4b764689bc8e256e43ba76f1 rdf:first N687334989a694ad68764d4e781c09e6d
182 rdf:rest N5c005520ffc6451e91900dde5ec33462
183 Nbc840e131bc64709b821d02de5bc342a schema:volumeNumber 7
184 rdf:type schema:PublicationVolume
185 Nbcf502627d1c4ca08781e2e031d1afa6 rdf:first N1b72b16f1cde48358dd032b17c5327b6
186 rdf:rest N4fe31debdf51464d940dbbbbe0a7412b
187 Nc193146f825c42fd8e779e4831b59d53 rdf:first N5f3f3a072b4148f5a4304e3bf5e5c8de
188 rdf:rest N50bf84228d934f49b1f66cf1e6efeb12
189 Ncaa9395b223f4dc99b99804dab7e945a rdf:first Nbad4545dc94848b59b40b5e9c222f858
190 rdf:rest N7c35447d437f4a83821b61c53bb85895
191 Nd054990915b8479081442a9dd2397b03 rdf:first N80eecdaee6aa45b2874373c11c28c1c6
192 rdf:rest Nff018a8dde7648efa2bb2f873fbed49d
193 Nd0b20ec2dbd34c058093b61b4f96321a schema:affiliation https://www.grid.ac/institutes/grid.417893.0
194 schema:familyName Raimondi
195 schema:givenName Alessandra
196 rdf:type schema:Person
197 Nd6a3e5ad8e3c411f9b7b3cbb6f4195c1 rdf:first Nabee962333594ffea5fd86cce7719462
198 rdf:rest Nc193146f825c42fd8e779e4831b59d53
199 Neb84247121c94b078a4a828e0e3111c8 schema:affiliation N4604c8eb315b44549e6561b4886ebbf6
200 schema:familyName Cappuzzo
201 schema:givenName Federico
202 rdf:type schema:Person
203 Nf13bdfecb74748dd8e02ca780d5fb3f5 schema:affiliation https://www.grid.ac/institutes/grid.415207.5
204 schema:familyName Turci
205 schema:givenName Daniele
206 rdf:type schema:Person
207 Nf1adf4b68a684d81bcf884a7658824f4 schema:affiliation https://www.grid.ac/institutes/grid.417520.5
208 schema:familyName Cognetti
209 schema:givenName Francesco
210 rdf:type schema:Person
211 Nf989ba2aae9d4b71b888a15d08ed93ab schema:name dimensions_id
212 schema:value pub.1113181867
213 rdf:type schema:PropertyValue
214 Nfb2e6c402d614403b452f808ca1a47b9 rdf:first Neb84247121c94b078a4a828e0e3111c8
215 rdf:rest N1a508a60eada40b5849dcc7f21ca70f1
216 Nfbc03964eaea4c8aa5e5b1f56d119d76 rdf:first Nd0b20ec2dbd34c058093b61b4f96321a
217 rdf:rest Nbaf5aa6b4b764689bc8e256e43ba76f1
218 Nff018a8dde7648efa2bb2f873fbed49d rdf:first Nf1adf4b68a684d81bcf884a7658824f4
219 rdf:rest Nd6a3e5ad8e3c411f9b7b3cbb6f4195c1
220 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
221 schema:name Medical and Health Sciences
222 rdf:type schema:DefinedTerm
223 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
224 schema:name Oncology and Carcinogenesis
225 rdf:type schema:DefinedTerm
226 sg:journal.1049249 schema:issn 2051-1426
227 schema:name Journal for ImmunoTherapy of Cancer
228 rdf:type schema:Periodical
229 https://doi.org/10.1001/jamadermatol.2015.1916 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032824188
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1001/jamaoncol.2015.2274 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017475370
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1016/j.ejca.2015.11.016 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034148114
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1016/j.eururo.2017.02.010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084074059
236 rdf:type schema:CreativeWork
237 https://doi.org/10.1016/j.jtho.2017.08.022 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091880982
238 rdf:type schema:CreativeWork
239 https://doi.org/10.1056/nejmoa1200690 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042896583
240 rdf:type schema:CreativeWork
241 https://doi.org/10.1056/nejmoa1510665 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019970557
242 rdf:type schema:CreativeWork
243 https://doi.org/10.1080/17425255.2016.1214713 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006340760
244 rdf:type schema:CreativeWork
245 https://doi.org/10.1080/2162402x.2016.1231292 schema:sameAs https://app.dimensions.ai/details/publication/pub.1058420756
246 rdf:type schema:CreativeWork
247 https://doi.org/10.1093/annonc/mdw640 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059394941
248 rdf:type schema:CreativeWork
249 https://doi.org/10.1097/cji.0000000000000046 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006229006
250 rdf:type schema:CreativeWork
251 https://doi.org/10.1097/cji.0b013e318156e47e schema:sameAs https://app.dimensions.ai/details/publication/pub.1015171108
252 rdf:type schema:CreativeWork
253 https://doi.org/10.1111/bju.14461 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105203453
254 rdf:type schema:CreativeWork
255 https://doi.org/10.1158/1078-0432.ccr-07-0187 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049037424
256 rdf:type schema:CreativeWork
257 https://doi.org/10.1158/1078-0432.ccr-15-1136 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063224982
258 rdf:type schema:CreativeWork
259 https://doi.org/10.1200/jco.2005.06.205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021025524
260 rdf:type schema:CreativeWork
261 https://doi.org/10.1200/jco.2014.57.4756 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043986240
262 rdf:type schema:CreativeWork
263 https://doi.org/10.1200/jco.2015.60.8448 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009760042
264 rdf:type schema:CreativeWork
265 https://doi.org/10.1200/jco.2015.66.1389 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079388627
266 rdf:type schema:CreativeWork
267 https://doi.org/10.1200/jco.2016.34.15_suppl.3047 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106841583
268 rdf:type schema:CreativeWork
269 https://doi.org/10.1200/jco.2017.77.6385 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101034912
270 rdf:type schema:CreativeWork
271 https://doi.org/10.1212/wnl.0000000000004359 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091248943
272 rdf:type schema:CreativeWork
273 https://doi.org/10.1371/journal.pone.0053745 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032246329
274 rdf:type schema:CreativeWork
275 https://doi.org/10.1634/theoncologist.2017-0133 schema:sameAs https://app.dimensions.ai/details/publication/pub.1086386152
276 rdf:type schema:CreativeWork
277 https://doi.org/10.1634/theoncologist.2017-0384 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105038826
278 rdf:type schema:CreativeWork
279 https://doi.org/10.3390/cancers10020032 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100657075
280 rdf:type schema:CreativeWork
281 https://www.grid.ac/institutes/grid.410345.7 schema:alternateName Ospedale San Martino
282 schema:name Medical Oncology, San Martino Hospital, Genoa, Italy.
283 rdf:type schema:Organization
284 https://www.grid.ac/institutes/grid.411482.a schema:alternateName Ospedale di Parma
285 schema:name Medical Oncology, Azienda Ospedaliera di Parma, Parma, Italy.
286 rdf:type schema:Organization
287 https://www.grid.ac/institutes/grid.413172.2 schema:alternateName Ospedale Antonio Cardarelli
288 schema:name Oncology Unit, A. Cardarelli Hospital, Naples, Italy.
289 rdf:type schema:Organization
290 https://www.grid.ac/institutes/grid.413363.0 schema:alternateName Policlinico di Modena
291 schema:name Oncology and Hematology Department, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy.
292 rdf:type schema:Organization
293 https://www.grid.ac/institutes/grid.414614.2 schema:alternateName Ospedale Infermi di Rimini
294 schema:name Oncology, Ospedale Infermi, Rimini, Italy.
295 rdf:type schema:Organization
296 https://www.grid.ac/institutes/grid.415207.5 schema:alternateName Ospedale Santa Maria delle Croci
297 schema:name Medical Oncology, Ospedale Santa Maria delle Croci, Ravenna, Italy.
298 rdf:type schema:Organization
299 https://www.grid.ac/institutes/grid.416377.0 schema:alternateName Azienda Ospedaliera S.Maria
300 schema:name Medical Oncology, Azienda Ospedaliera Santa Maria, Terni, Italy.
301 rdf:type schema:Organization
302 https://www.grid.ac/institutes/grid.417007.5 schema:alternateName Policlinico Umberto I
303 schema:name Radiology, Oncology and Pathology, Policlinico Umberto I, Rome, Italy.
304 rdf:type schema:Organization
305 https://www.grid.ac/institutes/grid.417011.2 schema:alternateName Ospedale Vito Fazzi
306 schema:name Medical Oncology, Ospedale Vito Fazzi, Lecce, Italy.
307 rdf:type schema:Organization
308 https://www.grid.ac/institutes/grid.417520.5 schema:alternateName Istituti Fisioterapici Ospitalieri
309 schema:name Biostatistical Unit, Regina Elena National Cancer Institute - IRCCS, Rome, Italy.
310 Medical Oncology, Regina Elena National Cancer Institute - IRCCS, Rome, Italy.
311 rdf:type schema:Organization
312 https://www.grid.ac/institutes/grid.417893.0 schema:alternateName Istituto Nazionale dei Tumori
313 schema:name Medical Oncology-Genitourinary Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Via Venezian 1, 20133, Milan, Italy.
314 Medical Oncology-Genitourinary Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Via Venezian 1, 20133, Milan, Italy. elena.verzoni@istitutotumori.mi.it.
315 Urology and Gynecology, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Naples, Italy.
316 rdf:type schema:Organization
317 https://www.grid.ac/institutes/grid.419450.d schema:alternateName Istituti Ospitalieri di Cremona
318 schema:name Medical Oncology, Istituti Ospitalieri di Cremona, Cremona, Italy.
319 rdf:type schema:Organization
320 https://www.grid.ac/institutes/grid.419563.c schema:alternateName Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
321 schema:name Urologic-Gynecologic Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy.
322 rdf:type schema:Organization
323 https://www.grid.ac/institutes/grid.8982.b schema:alternateName University of Pavia
324 schema:name Department of Internal Medicine, University of Pavia and Division of Translational Oncology, IRCCS Istituti Clinici Scientifici Maugeri, Pavia, Italy.
325 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...